IDH2 inhibitorFDA-approvedInvestigational
Enasidenib
How it works
Blocks the IDH2 enzyme, which is involved in the regulation of cellular metabolism and proliferation in leukemia cells.
Cancer types
Leukemia— IDH2-mutated
Efficacy
In clinical trials, around 40% of IDH2-mutated patients achieved an objective response, with a median overall survival of approximately 8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Azacitidine and Enasidenib for IDH2-Mutant Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Testing Gilteritinib with Ivosidenib or Enasidenib for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Enasidenib for Acute Myeloid Leukemia After Stem Cell Transplant | Leukemia | phase-2 | — | Source → |
| New Lab Method for Measuring Cancer Drug in Human Cells | Leukemia | lab-study | — | Source → |
| Combination Therapy Shows Promise in Treating Leukaemia | Leukemia | phase-1/2 | The overall response rate was 62% (95% CI 41-80; 16 of 26) in patients with AML. | Source → |
| Enasidenib Shows Promise for Treating AML with IDH2 Mutation | Leukemia | observational | The overall response rate was 39.1% and the morphological complete remission rate was 26.1%. | Source → |
| New Study Tests Enasidenib for Early-Stage Leukemia | Leukemia | phase-2 | The composite complete response rate (CR/CRi) was 46% in 60 evaluable patients. | Source → |
| Combination Therapy Shows Promise for Patients with Certain Type of Leukemia | Leukemia | phase-2 | The composite complete remission rate was 100% in newly diagnosed AML patients, and 58% in relapsed/refractory AML patients. | Source → |
| Combining Cancer Drugs Enhances Leukemia Cell Differentiation | Leukemia | lab-study | Combination treatment enhanced cellular differentiation in TF-1 cells overexpressing IDH2R140Q through increased hemoglobinization and increased hemoglobin γ RNA expression compared with the effects of single agents. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.